在伊马替尼治疗期间,CFL1与慢性髓性白血病反应有关
Xiufeng Yin1, Xia Li2, Hao Jiang1
1Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, P R China.
Journal of Cancer
|March 18, 2024
概括
慢性髓性白血病 (CML) 患者的较低的cofilin (CFL1) 表达预测了对伊马替尼治疗的更好的反应. 伊马替尼可上调CFL1,影响CML中的actin重塑.
科学领域:
- 分子生物学分子生物学
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 作为一种actin-depolymerizing因子的cofilin (CFL1),与癌症的进展有关.
- 过度表达CFL1与恶性瘤特征和预后不佳相关.
- 在慢性髓性白血病 (CML) 中CFL1的作用及其对伊马替尼治疗的反应需要阐明.
研究的目的:
- 与健康对照组相比,评估慢性髓性白血病慢性阶段 (CML-CP) 和急性髓性白血病 (AML) 的患者的CFL1表达.
- 调查CFL1在CML中伊马替尼治疗反应中的作用.
主要方法:
- 在CML-CP,AML患者和健康对照中分析CFL1的表达.
- 在体外细胞系研究以评估在伊马替尼治疗期间CFL1的作用.
- 量化cofilin,酸化cofilin和F-actin水平在imatinib治疗后.
主要成果:
- 与健康对照组相比,CFL1表达在CML患者中较低.
- 伊马替尼布治疗显著上调了CML患者的CFL1表达 (p<0.05).
- 基线较低的CFL1表达与6个月伊马替尼治疗后更高的主要分子响应 (MMR) 率相关 (p<0.05).
- 伊马替尼布治疗增加了科菲林,P-科菲林和F-actin (特别是分支F-actin) 的水平.
结论:
- 治疗前CFL1表达的减少可以作为预测生物标志物,用于在CML中对伊马替尼布更好的反应.
- 伊马替尼通过调节CFL1的表达和活性来影响CML中的F-actin重塑.
- 在慢性髓性白血病中,CFL1在对伊马替尼的治疗反应中起着重要作用.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K


